Netherlands vs Switzerland: The number of people with susceptibility test result for rifampicin
Netherlands
86.26
in 2021
Switzerland
87.3
in 2021
Netherlands rank
82nd
Switzerland rank
79th
The number of people with susceptibility test result for rifampicin over time
- Netherlands
- Switzerland
How they compare
Switzerland currently reports 87.3 against 86.26 in Netherlands, a difference of 1.04.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Netherlands ahead.
Netherlands ranks 82nd and Switzerland ranks 79th of 146 countries.
Switzerland has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Netherlands | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 88.98 | 92.97 | 3.99 | Switzerland |
| 2020s | 86.86 | 88.89 | 2.03 | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Netherlands or Switzerland?
- Switzerland, at 87.3 against 86.26 in Netherlands as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Netherlands and Switzerland?
- 1.04, with Switzerland ahead.
- How many years of comparable data are there for Netherlands and Switzerland?
- 5 years are reported by both, from 2017 to 2021.
- How do Netherlands and Switzerland rank globally for the number of people with susceptibility test result for rifampicin?
- Netherlands ranks 82nd and Switzerland ranks 79th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.